Introduction
Dale in 1914 first showed that acetylcholine produced two types of response, which were mimicked by nicotine and by muscarine, and that the muscarinic action was blocked by atropine.' Only very recently, however, have muscarinic receptors been subdivided. This has been made possible by the development of selective drugs, and muscarinic receptor subtypes have now been identified in several tissues. 23 The evidence for muscarinic receptor subtypes was initially challenged, but advances in molecular biology have confirmed their existence and as many as five different receptor subtypes have now been cloned and expressed." The precise relation between these cloned receptor subtypes and receptors identified pharmacologically, however, is still not clear and the drugs that differentiate receptor subtypes lack a high degree of selectivity.
Muscarnnic receptor classification
There is still some confusion over the classification and nomenclature of muscarinic receptors. At least three distinct receptor subtypes have been differentiated pharmacologically, both by radioligand binding assays and by functional studies. 8 Pirenzepine was the first selective muscarinic antagonist to be recognised,9 and pirenzepine sensitive muscarinic receptors are termed Ml receptors. Other muscarinic receptors were termed M2 receptors, until it became clear that they were heterogeneous as new antagonists, such as AF-DX 116'°and methoctramine,"t 12 were developed. M2 receptors in atria were clearly different from those in smooth muscle and glands, which have now been termed M3 receptors. M3 receptors are selectively blocked by 4-diphenylacetoxy-N-methyl piperidine methiodide (4-DAMP) and hexahydrosiladifenidine. Further subdivision may be possible with the development of more selective drugs. In normal subjects pilocarpine, which selectively stimulates prejunctional receptors (but has some direct effect on airway smooth muscle receptors and so causes bronchoconstriction), had an inhibitory effect on cholinergic reflex bronchoconstriction induced by sulphur dioxide, whereas a similar degree of bronchoconstriction with histamine did not affect the bronchoconstriction induced by sulphur dioxide." This suggests that these inhibitory receptors may be present in vivo, presumably serving to limit cholinergic bronchoconstriction. In asthmatic patients pilocarpine had no such inhibitory action, indicating that there might be some dysfunction of the autoreceptor; this might result in exaggerated cholinergic reflex bronchoconstriction." The reason why muscarinic autoreceptors may be dysfunctional in asthma is not certain. Possibly inflammatory changes in the airways lead to a reduction in muscarinic receptor number or coupling. This would have little or no effect on airway smooth muscle muscarinic receptors, which are very much in excess, but there may not be as many "spare" prejunctional receptors and they would therefore be more susceptible to damage.
M3 RECEPTORS
The muscarinic receptors on airway smooth muscle are sensitive to 4-DAMP and hexahydrosiladifenidol and are therefore classified as M3 receptors. Binding studies in guinea pig lung membranes indicate a preponderance of M3 receptors, whereas in human lung M3 receptors make up less than half of the receptors (the remainder being M,).36 Autoradiographic mapping studies have shown that M3 receptors are localised to airway smooth muscle and to submucosal glands. 37 The discovery of at least three muscarinic subtypes in the lung has important clinical implications, as it raises the possibility of more selective anticholinergic treatment in the future. Atropine, ipratropium bromide, and oxitropium bromide are non-selective anticholinergic drugs blocking prejunctional (M2) and postjunctional (M3) receptors with equal affinity. Inhibition ofthe autoreceptor means that more acetylcholine will be released during cholinergic nerve stimulation and this may overcome postjunctional blockade, thus making these non-selective antagonists less efficient than a selective antagonist of M2 receptors. Alpha adrenoreceptors are analogous; the nonselective antagonist phentolamine, by acting on a prejunctional alpha2 receptor, increases noradrenaline release and is thus far less effective in the treatment of hypertension than a selective alpha, antagonist such as prazosin, which acts only on the postjunctional receptor. Unfortunately 
Beta blocker induced asthma
The worsening of asthma by beta blocking drugs remains a problem and deaths continue to be reported. Even beta blocker eye drops are capable of precipitating an asthma attack. 49 The cause has remained elusive, although cholinergic mechanisms may have a critical role as anticholinergic drugs may completely prevent the bronchoconstriction due to inhaled propranolol.5' Muscarinic autoreceptors might help to explain how catastrophic bronchoconstriction may be precipitated by even a small dose of a beta blocking drug. Beta blocking drugs inhibit adrenergic bronchodilator tone, which in man is probably provided by circulating adrenaline.5 Beta2 receptors that when activated inhibit the release of acetylcholine have now been found on cholinergic nerves of human bronchi,52 and when these are blocked an increase in tonic acetylcholine release would be expected. In normal individuals the acetylcholine would activate these autoreceptors to shut off any further acetylcholine release and thus no bronchoconstriction would occur. In asthmatic patients the same increase in acetylcholine would occur but, because of the apparent defect in muscarinic autoreceptors,4 there would be no mechanism for switching off acetylcholine release. Furthermore, the asthmatic airway is hyperresponsive to acetylcholine, and thus even low doses of a beta blocker may precipitate a catastrophic bronchoconstrictor response (fig 2) .
Summary and conclusions
Several subtypes of muscarinic receptor have now been identified and have been found recently in the airways of several species, including man, a discovery that may have important clinical implications. M, receptors may be found in parasympathetic ganglia, M2 receptors on cholinergic nerves (autoreceptors), and M3 receptors on airway smooth muscle and mucus secreting glands. It is suggested that a defect in M2 receptor function may help to explain why asthma may be induced by beta blocking drugs. Further elucidation of the physiological role for these receptor subtypes will probably depend on the development of more selective antagonists. Drugs such as methoctramine, which have a high degree of selectivity for M2 receptors, are promising tools for elucidating the role of muscarinic receptor subtypes," but drugs with a higher selectivity for Ml and M3 receptors are likely to be most useful clinically in airway disease; in particular, M3 blockers will not be associated with increased acetylcholine release. The recent availability
